ABCL

Conviction 92HealthcareScan · Fri, Jun 26, 2026

Bullish marubozu

ABCL$7.37+10.66%

ResistanceSupportVol 14Insider buy

Vol MA14 7.11M

Mar 27Apr 15May 4May 20Jun 9Jun 26

AbCellera Biologics Inc.PHARMACEUTICAL PREPARATIONSwww.abcellera.com ↗

Price7.37

Change+10.66%

Gap-2.63%

Rel volume3.15×

Avg volume7.71M

Avg $ vol46.89M

SMA 205.78

SMA 505.03

SMA 2004.31

Price vs 50+46.42%

Price vs 200+70.94%

MA stackbullish

50/200 cross—

Supertrendup · 5.23

RSI (14)73

MACD hist0.13

MACD crossbull · 1d

Stoch %K / %D99 / 83

ADX (14)37

+DI / −DI37 / 10

RSI divergence—

MACD divergence—

ATR %+7.37%

ADR %9.52%

52w high7.37

52w low2.78

From 52w high+0.00%

Above 52w low+165.11%

New 52w highYes

SqueezeOff

Bollinger width40.42%

%B1.18

Donchian pos98.74%

Donchian high7.40

Donchian low5.01

AVWAP (52w high)7.09

vs AVWAP high+4.02%

AVWAP (52w low)4.64

vs AVWAP low+58.78%

OBV trendUp

Chaikin MF (20)0.11

Today vs 20d3.15×

Avg vol (14d)7.11M

Avg vol (20d)7.71M

Avg $ vol (20d)46.89M

Market cap—

RS 3m (vs SPY)+84.66%

RS 6m (vs SPY)+71.81%

RS line new highYes

Trend template6/8

Technical rank96.3

1 week+33.27%

1 month+35.48%

3 months+120.00%

6 months+99.73%

1 year+93.95%

YTD+114.87%

P/E-13.87

P/B2.16

P/S27.03

P/FCF-11.67

EPS-0.4900

Div yield—

ROE-15.61%

ROA-11.20%

Debt/Eq0.00

Current14.05

EV/EBITDA—

Gross margin—

Net margin-194.88%

Rev growth160.56%

EPS growth10.10%

Price target9.40

Target upside41.35%

Analyst ratingBuy

Institutional42.27%

Ent. value1.95B

Revenue8.31M

Net income-43.16M

Gross profit—

Free cash flow-174.07M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out305.38M

Employees562

ListedFri, Dec 11, 2020

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction92 / 100

Pattern quality—

Tech rank96.3 / 100

Group rank50 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmBullish marubozu

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ABCL

All disclosures →

No recent disclosed trades by Congress in ABCL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ABCL · 5 buys · 1 sell

Insider	Side	Shares	Value	Traded	Filed
Hayden Michael R Director · Share option (right to buy) · 2026-06-11	Grant	111.7K	—	2026-06-11	2026-06-12
Quake Stephen Director · Share option (right to buy) · 2026-06-11	Grant	111.7K	—	2026-06-11	2026-06-12
Montalbano John S. Director · Share option (right to buy) · 2026-06-11	Grant	111.7K	—	2026-06-11	2026-06-12
Booth Andrew Chief Financial Officer · Common Shares · 2026-06-03	Other	—	—	2026-06-03	2026-06-03
Booth Andrew Chief Financial Officer · Share option (right to buy) · 2026-06-03	Exercise	250K	$0	2026-06-03	2026-06-03
Booth Andrew Chief Financial Officer · Common Shares · 2026-06-03	Exercise	250K	$48K	2026-06-03	2026-06-03
Montalbano John S. Director · Common Shares · 2026-05-14	Other	—	—	2026-05-14	2026-05-18
Montalbano John S. Director · Common Shares · 2026-05-14	Buy	20K	$95K	2026-05-14	2026-05-18

SEC filings

EDGAR filings in ABCL · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.